Invesco Exchange-Traded Fund Trust. Holdings as of Jul 31, 2026, from Form N-PORT.
Share of net assets at the report date, for the whole fund across all share classes.
| Holding | Weight | Value | Shares or units |
|---|---|---|---|
| Invesco Private Prime FundCash or money market | 20.79% | $48.91M | 48,906,882 |
| Invesco Private Government FundCash or money market | 6.83% | $16.08M | 16,076,714 |
| Guardant Health, Inc.GH | 4.97% | $11.70M | 72,199 |
| Roivant Sciences Ltd.ROIV | 4.95% | $11.63M | 343,019 |
| Revolution Medicines, Inc.RVMD | 4.94% | $11.61M | 61,927 |
| Axsome Therapeutics, Inc.AXSM | 4.12% | $9.70M | 44,490 |
| BrightSpring Health Services, Inc.BTSG | 4.03% | $9.48M | 158,696 |
| Liquidia Corp.LQDA | 3.01% | $7.08M | 84,234 |
| Erasca, Inc.ERAS | 2.94% | $6.92M | 381,019 |
| Oruka Therapeutics, Inc.ORKA | 2.74% | $6.44M | 66,716 |
| 10x Genomics, Inc.TXG | 2.27% | $5.34M | 112,984 |
| Relay Therapeutics, Inc.RLAY | 2.25% | $5.29M | 280,758 |
| Tango Therapeutics Inc.TNGX | 2.16% | $5.07M | 186,706 |
| Travere Therapeutics, Inc.TVTX | 2.16% | $5.07M | 90,742 |
| Oscar Health, Inc.OSCR | 2.10% | $4.93M | 158,058 |
| Illumina, Inc.ILMN | 2.08% | $4.89M | 23,863 |
| agilon health, Inc.AGL | 2.07% | $4.86M | 53,027 |
| Axogen, Inc.AXGN | 2.06% | $4.84M | 114,692 |
| Arrowhead Pharmaceuticals, Inc.ARWR | 2.01% | $4.74M | 55,978 |
| Spyre Therapeutics, Inc.SYRE | 2.01% | $4.73M | 48,127 |
| Replimune Group, Inc.REPL | 1.93% | $4.54M | 405,048 |
| Jazz Pharmaceuticals PLCJAZZ | 1.93% | $4.53M | 17,925 |
| Moderna, Inc.MRNA | 1.90% | $4.46M | 81,355 |
| Cytokinetics, Inc.CYTK | 1.89% | $4.44M | 57,568 |
| Viatris Inc.VTRS | 1.82% | $4.28M | 243,859 |
| Centene Corp.CNC | 1.79% | $4.20M | 67,565 |
| Humana Inc.HUM | 1.77% | $4.16M | 11,434 |
| Ligand Pharmaceuticals Inc.LGND | 1.74% | $4.10M | 14,247 |
| Corcept Therapeutics Inc.CORT | 1.71% | $4.03M | 35,225 |
| Enliven Therapeutics, Inc.ELVN | 1.70% | $3.99M | 72,884 |
| Twist Bioscience Corp.TWST | 1.59% | $3.74M | 40,860 |
| Hims & Hers Health, Inc.HIMS | 1.57% | $3.70M | 133,217 |
| MBX Biosciences, Inc.MBX | 1.53% | $3.60M | 54,646 |
| Arcutis Biotherapeutics, Inc.ARQT | 1.53% | $3.59M | 133,630 |
| Establishment Labs Holdings Inc. | 1.51% | $3.55M | 38,410 |
| uniQure N.V. | 1.50% | $3.54M | 81,027 |
| PACS Group, Inc.PACS | 1.33% | $3.13M | 68,052 |
| Exelixis, Inc.EXEL | 1.31% | $3.09M | 58,311 |
| Trevi Therapeutics, Inc.TRVI | 1.17% | $2.75M | 150,679 |
| Krystal Biotech, Inc.KRYS | 1.17% | $2.75M | 8,055 |
| National HealthCare Corp.NHC | 1.12% | $2.63M | 11,635 |
| Amneal Pharmaceuticals, Inc.AMRX | 1.12% | $2.63M | 143,351 |
| Alkermes PLC | 1.10% | $2.58M | 52,682 |
| Veracyte, Inc.VCYT | 1.09% | $2.56M | 55,185 |
| NeoGenomics, Inc.NEO | 1.08% | $2.53M | 165,576 |
| Nuvation Bio Inc.NUVB | 1.06% | $2.50M | 394,869 |
| TG Therapeutics, Inc.TGTX | 1.06% | $2.48M | 47,707 |
| AbSci Corp.ABSI | 0.99% | $2.34M | 300,499 |
| Denali Therapeutics Inc.DNLI | 0.97% | $2.29M | 99,311 |
| Disc Medicine, Inc.IRON | 0.89% | $2.09M | 27,202 |
Holdings from the fund's latest Form N-PORT; expense ratio (net of fee waivers) from the risk/return summary of its prospectus; fund type from Form N-CEN. Prices are end-of-day closes adjusted for splits; total return also reinvests distributions.